Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Lenacapavir

These are related to the Lenacapavir news, in which you can learn about the latest trends in Lenacapavir and related information industry, to help you better understand and expand Lenacapavir market.
  • Drug Briefing: Lenacapavir

    Drug Briefing: Lenacapavir

    2024-06-24

    Query Drug：LenacapavirQuery Time：2024-06-24 11:06:36*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
  • Groundbreaking HIV Prevention Drug Shows 100% Efficacy in Phase 3 Trial

    Groundbreaking HIV Prevention Drug Shows 100% Efficacy in Phase 3 Trial

    2024-06-24

    A recent Phase 3 clinical trial (NCT04994509), dubbed "PURPOSE 1," has yielded promising results for a new HIV prevention drug, potentially revolutionizing the field of HIV prophylaxis. The study, conducted by Gilead Sciences, evaluated the safety and efficacy of Lenacapavir, a novel long-acting HIV Read More
  • Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor

    Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor

    2023-10-13

    In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't Read More